Tags

Type your tag names separated by a space and hit enter

Evaluation of cytomegalovirus-specific cytotoxic T-lymphocytes in patients with the HLA-A*02 or HLA-A*24 phenotype undergoing hematopoietic stem cell transplantation.
Bone Marrow Transplant. 2005 Nov; 36(9):803-11.BM

Abstract

Cytomegalovirus-specific cytotoxic T-lymphocytes (CMV-CTL) are essential for the control of CMV reactivation. To monitor the quantity and function of CMV-CTL after hematopoietic stem cell transplantation (HSCT), two CMV epitopes that bind to HLA-A*0201 NLVPMVATV (A*02NLV) and HLA-A*2402 QYDPVAALF (A*24QYD) were evaluated for their immunological potential. Samples from patients with the HLA-A*02 or HLA-A*24 serotype were analyzed by tetramer, intracellular cytokine staining and enzyme-linked immunospot (ELISPOT) assay. There were significantly more A*02NLV-specific CMV-CTL than A*24QYD (23 x 10(6) vs 0.4 x 10(6)/l). The frequency of IFN-gamma-producing cells was also higher upon stimulation with A*02NLV than with A*24QYD (2.5 vs 0.1%/CD8). Furthermore, the magnitude of CMV-CTL expansion was two- to 50-fold when cells were cultured with A*02NLV, while only an insignificant increase was observed in culture with A*24QYD. Although the number of A*24QYD-specific CMV-CTL was very low in most of the HLA-A*24 patients, the incidence of CMV reactivation did not differ between those with HLA-A*02 and HLA-A*24 serotype alone. These results suggest that an epitope other than A*24QYD plays a major role in patients with HLA-A*24. Our study also showed that A*02NLV may be a useful epitope for monitoring CMV-CTL not only in patients with HLA-A*0201 but also in those with the A*0206 genotype.

Authors+Show Affiliations

Division of Hematology and Stem Cell Transplantation, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16113668

Citation

Morita, Y, et al. "Evaluation of Cytomegalovirus-specific Cytotoxic T-lymphocytes in Patients With the HLA-A*02 or HLA-A*24 Phenotype Undergoing Hematopoietic Stem Cell Transplantation." Bone Marrow Transplantation, vol. 36, no. 9, 2005, pp. 803-11.
Morita Y, Hosokawa M, Ebisawa M, et al. Evaluation of cytomegalovirus-specific cytotoxic T-lymphocytes in patients with the HLA-A*02 or HLA-A*24 phenotype undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;36(9):803-11.
Morita, Y., Hosokawa, M., Ebisawa, M., Sugita, T., Miura, O., Takaue, Y., & Heike, Y. (2005). Evaluation of cytomegalovirus-specific cytotoxic T-lymphocytes in patients with the HLA-A*02 or HLA-A*24 phenotype undergoing hematopoietic stem cell transplantation. Bone Marrow Transplantation, 36(9), 803-11.
Morita Y, et al. Evaluation of Cytomegalovirus-specific Cytotoxic T-lymphocytes in Patients With the HLA-A*02 or HLA-A*24 Phenotype Undergoing Hematopoietic Stem Cell Transplantation. Bone Marrow Transplant. 2005;36(9):803-11. PubMed PMID: 16113668.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of cytomegalovirus-specific cytotoxic T-lymphocytes in patients with the HLA-A*02 or HLA-A*24 phenotype undergoing hematopoietic stem cell transplantation. AU - Morita,Y, AU - Hosokawa,M, AU - Ebisawa,M, AU - Sugita,T, AU - Miura,O, AU - Takaue,Y, AU - Heike,Y, PY - 2005/8/23/pubmed PY - 2006/1/13/medline PY - 2005/8/23/entrez SP - 803 EP - 11 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 36 IS - 9 N2 - Cytomegalovirus-specific cytotoxic T-lymphocytes (CMV-CTL) are essential for the control of CMV reactivation. To monitor the quantity and function of CMV-CTL after hematopoietic stem cell transplantation (HSCT), two CMV epitopes that bind to HLA-A*0201 NLVPMVATV (A*02NLV) and HLA-A*2402 QYDPVAALF (A*24QYD) were evaluated for their immunological potential. Samples from patients with the HLA-A*02 or HLA-A*24 serotype were analyzed by tetramer, intracellular cytokine staining and enzyme-linked immunospot (ELISPOT) assay. There were significantly more A*02NLV-specific CMV-CTL than A*24QYD (23 x 10(6) vs 0.4 x 10(6)/l). The frequency of IFN-gamma-producing cells was also higher upon stimulation with A*02NLV than with A*24QYD (2.5 vs 0.1%/CD8). Furthermore, the magnitude of CMV-CTL expansion was two- to 50-fold when cells were cultured with A*02NLV, while only an insignificant increase was observed in culture with A*24QYD. Although the number of A*24QYD-specific CMV-CTL was very low in most of the HLA-A*24 patients, the incidence of CMV reactivation did not differ between those with HLA-A*02 and HLA-A*24 serotype alone. These results suggest that an epitope other than A*24QYD plays a major role in patients with HLA-A*24. Our study also showed that A*02NLV may be a useful epitope for monitoring CMV-CTL not only in patients with HLA-A*0201 but also in those with the A*0206 genotype. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/16113668/Evaluation_of_cytomegalovirus_specific_cytotoxic_T_lymphocytes_in_patients_with_the_HLA_A_02_or_HLA_A_24_phenotype_undergoing_hematopoietic_stem_cell_transplantation_ L2 - https://doi.org/10.1038/sj.bmt.1705133 DB - PRIME DP - Unbound Medicine ER -